Jean-Jacques Bienaime, CEO of drugmaker BioMarin, discussed the impact of 340B on pharmaceutical sales during an investor earnings call.

Drugmakers Highlight 340B Developments in Earnings Calls

December 12, 2023 Rich Daly Editor in Chief Views

Pharmaceutical company executives discussed a range of 340B-related developments in recent third quarter investor calls. An executive for BioMarin Pharmaceutical, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Drugmakers Highlight 340B Developments in Earnings Calls

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly